Division of Albireo Pharma Inc.
Latest From Albireo AB
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Pipeline Watch has been updated to bring greater depth and detail to a product’s progress through the R&D pipeline, and is now a snapshot of late-stage, Phase II and III clinical trial events for drugs being evaluated by the pharma and biotech industries that is now available to view.
AstraZeneca’s Shaun Grady is an affable dealmaker whose talents – honed over three decades inside the group – are being put to the test as global business development head to help ensure Britain’s second-biggest drugmaker can successfully transform itself, its therapy focus and pipeline. He tells In Vivo about his role leading AZ’s transaction execution, due diligence and alliance and integration management, while overseeing its collaborative “externalization” program, licensing and partnering, M&A and divestments.
David Chiswell has worked tirelessly to build up the British biotech industry for over 30 years. Now, as CEO of Kymab, he is looking to the future of the industry and how to find the stars of the future.
- Therapeutic Areas
- Hepatic (Liver)
- Western Europe
- Parent & Subsidiaries
- Albireo Pharma Inc.
- Senior Management
Ron Cooper, Pres. & CEO
Per-Goran Gillberg, PhD, VP, Dev.
Hans Graffner, MD, PhD, CMO
- Contact Info
Phone: (46) 31 741 14 80
Arvid Wallgrens Backe 20
Gothenburg, 413 46
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.